Alector Q2 EPS $0.12 Up From $(0.69) YoY, Sales $79.85M Up From $6.57M YoY
Alector (NASDAQ:ALEC) reported quarterly earnings of $0.12 per share. This is a 117.39 percent increase over losses of $(0.69) per share from the same period last year. The company reported $79.85 million in sales this
AbbVie Dumps An Early-Alzheimer’s Candidate Developing In Collaboration With Alector
AbbVie Inc (NYSE:ABBV) has decided to terminate the CD33 collaboration program with Alector Inc (NASDAQ:ALEC), developing AL003 for Alzheimer’s disease as one of…
Expert Ratings for Alector
Within the last quarter, Alector (NASDAQ:ALEC) has observed the following analyst ratings:
Mizuho Initiates Coverage On Alector with Buy Rating, Announces Price Target of $15
Mizuho analyst Graig Suvannavejh initiates coverage on Alector (NASDAQ:ALEC) with a Buy rating and announces Price Target of $15.
Alector, Inc. – Common Stock Q1 EPS $(0.54) Up From $(0.66) YoY, Sales $24.50M Up From $4.11M YoY
Alector, Inc. - Common Stock (NASDAQ:ALEC) reported quarterly losses of $(0.54) per share. This is a 18.18 percent increase over losses of $(0.66) per share from the same period last year. The company reported $24.50
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Alector Highlights Mid-Stage Study Data On Lead Dementia Drug
Alector Inc (NASDAQ: ALEC) is flashing some AL001 (latozinemab) Phase 2 data at an Alzheimer’s and Parkinson’s disease conference, this time in dementia with a different type of mutation: C9orf72.